Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

CeNeRx BioPharma Completes $13 Million Series C Financing

August 14, 2010 By Bio-Medicine.Org

RESEARCH TRIANGLE PARK, N.C., Aug. 13 /PRNewswire/ — CeNeRx
BioPharma, Inc., a clinical stage company developing and
commercializing innovative treatments for diseases of the central
nervous system (CNS), today announced completion of a $13 million
Series C financing.  Existing investors Perseus Soros
Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all
participated in the financing.  CeNeRx plans to use the
proceeds to conduct a Phase II trial of its improved formulation of
its novel antidepressant TriRima™.

“These funds will support the Phase II trial of TriRima
as monotherapy for treatment-resistant depression,” said Barry
Brand, Chief Executive Officer of CeNeRx.  “We are pleased
with the continuing confidence and support of our investors and
look forward to advancing the CeNeRx pipeline.”

CeNeRx is preparing to conduct a Phase II trial with an improved
formulation of its lead product candidate TriRima for
treatment-resistant depression.  TriRima is a selective
and reversible member of a novel class of drugs known as RIMAs, or
reversible inhibitors of monoamine oxidase A (MAO-A).  The
triple action mechanism of TriRima elevates the levels of
three key neurotransmitters that positively affect mood and
anxiety, compared to the one or two neurotransmitters addressed by
most current antidepressant drugs.  This triple action
mechanism may benefit patients not responding to traditional single
or dual action products, while the selectivity and reversibility of
TriRima are expected to eliminate or reduce the risk of
food-associated cardiovascular side effects of conventional MAO
inhibitors.

About CeNeRx BioPharma

CeNeRx is a privately held clinical-stage biopharmaceutical
company developing and commercializing innovative treatments for
diseases of the central nervous system.  CeNeRx’s most
advanced compound, a reversible inhibitor of

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech